Was ist heute mit Cepheid passiert?? - 500 Beiträge pro Seite

[mimer_de]

Cepheid (939017) in Frankfurt heute minus 17 Prozent. Gabs neue Zahlen? Die letzten Nachrichten (auch in den diversen Foren) waren doch ganz okay?!?!?

[luna3636]

@mimer_de,

gestern nachbörslich gab`s zahlen

Cepheid Reports Fourth Quarter 2001 Results


SUNNYVALE, Calif., Feb 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- Cepheid
(Nasdaq: CPHD), developers and marketers of rapid, on-site DNA detection
systems, today announced financial results for the fourth quarter and year ended
December 31, 2001.

Cepheid reported revenues of $3.2 million for the fourth quarter of 2001
compared to $2.6 million for the same quarter of 2000. For the year ended
December 31, 2001, revenues increased 61% to $11.4 million from $7.1 million for
the year ended December 31, 2000. This increase in revenues for the quarter and
twelve months ended December 31, 2001 was primarily due to an increase in
product sales of Cepheid`s Smart Cycler(R) systems, used for DNA analysis in
real time. The product was launched in May 2000.

Product sales for the quarter ended December 31, 2001 increased to $2.9 million
from $1.8 million for the same quarter of 2000, and increased from $1.9 million
for the third quarter ended September 30, 2001. A total of 117 Smart Cycler
systems and approximately 400,000 tubes were sold in the fourth quarter of 2001
compared to 76 Smart Cycler systems and approximately 237,000 tubes in the third
quarter of 2001.

Commenting on the company`s year-end results, Thomas Gutshall, Cepheid`s
Chairman and Chief Executive Officer stated, "The delivery of the prototype
GeneXpert(TM) system to the U.S. Army was a pivotal event in the history of the
company." Gutshall continued, "Importantly, GeneXpert represents the first fully
integrated system that incorporates the 3 steps of DNA analysis and provides
results within 30 minutes, where and when it is needed."

Cepheid reported a net loss of $4.2 million, or $0.16 per share for the fourth
quarter of 2001, compared to a net loss of $3.2 million, or $0.12 per share for
the same quarter in 2000. For the year ended December 31, 2001, Cepheid reported
a net loss of $15.5 million, or $0.60 per share compared to a net loss allocable
to common shareholders of $33.9 million, or $1.56 per common share on a pro
forma basis, for the same prior year period. In connection with the June 2000
initial public offering of Cepheid common shares, the fiscal year 2000 financial
results included a deemed dividend of $19.1 million incurred upon the issuance
of Series C convertible preferred stock in the first quarter of 2000. Pro forma
net loss per share amounts assume conversion of preferred stock to common at the
time of their original issuance.

The Company also provided guidance for the first quarter and full year 2002. For
the first quarter of 2002, the Company projects product sales of between $2.5
and $2.9 million and a net loss per share of between $0.19 and $0.20. For the
full year 2002, the Company reaffirms its projection that product sales will be
between $15 and $20 million and net loss per share will be between $0.63 and
$0.68 per share.

At December 31, 2001 the cash and cash equivalents, short term investments, and
restricted cash balance totaled $25.3 million. The Company`s operations used
$4.4 million in cash during the fourth quarter and $14.4 million for the year
ended December 31, 2001. The Company expects its monthly cash burn will average
$1.5 million during 2002.

As previously disclosed, the company filed a shelf registration statement with
the Securities and Exchange Commission that will permit the company, from time
to time, to offer and sell up to $35 million of its common stock, preferred
stock, debt securities and warrants. The company filed the registration
statement to gain additional flexibility in accessing capital markets for
general corporate purposes. The registration statement has not yet become
effective.

Conference Call Information

Cepheid will host a conference call to discuss the results for the quarter at
4:30 p.m. EST today. The call will be available via web cast live through the
Street Events website at www.streetevents.com or through Cepheid`s website at
(www.cepheid.com.) investor page at
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=CPHD&… .
Interested investors and media can also call 1-800-310-1961, pass code 626918 to
listen to the conference call. A replay of the call will be available starting
at 5:30 p.m. EST by dialing 1-888-203-1112, pass code 626918 or by accessing the
call on our website.

Cepheid, based in Sunnyvale, Calif., is commercializing its I-CORE(R) technology
as the preferred platform for rapid, on-site detection of DNA -- the universal
biological identifier -- for scientific, medical and industrial applications.
Sold directly and through its global network of partners, its Smart Cycler(R)
family of products provides researchers with quantitative DNA analysis in real
time, simultaneously supporting multiple users and protocols on a single
instrument with results in less than 30 minutes. Enabling time-critical DNA test
results at the point of need, Cepheid`s next-generation GeneXpert(TM) system
currently in development, is designed to provide the first automated integration
of all the steps required to detect DNA from complex biological specimens --
sample preparation, amplification and detection. Cepheid, I-CORE, Smart Cycler
and GeneXpert are registered trademarks of Cepheid. See www.cepheid.com.

Statements in this release other than statements of historical fact are
forward-looking statements. Forward-looking statements include those that may
relate to revenue growth, trends in financial or operational performance and
cash flows, new product plans, and business prospects. Actual results might
differ materially from these statements due to risks and uncertainties,
including the impact of competitive products and pricing, market acceptance of
new products, market conditions, reliance on efforts of distributors and
enforcement of intellectual property rights. A more detailed description of
these risks and other risks applicable to Cepheid appears in the following
materials Cepheid files with the Securities and Exchange Commission, which are
available upon request from Cepheid: periodic reports such as those on Form 10-Q
and 10-K, and the prospectus related to Cepheid`s most recent registration
statement, as amended and supplemented. Cepheid disclaims any intent or
obligation to update forward-looking statements.



CEPHEID

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)





Three months ended Year ended

December 31, December 31,

2001 2000 2001 2000

Revenues:

Product sales $2,896 $1,842 $8,656 $4,397

Service revenue 9 -- 13 --

License and royalty

revenue 70 -- 124 --

Grant and government

sponsored research

revenue 199 719 2,554 2,249

Research and development

contract revenue -- 73 7 416

Total revenues 3,174 2,634 11,354 7,062

Operating costs and

expenses:

Cost of product sales 1,694 1,627 6,330 3,851

Research and development 3,911 3,443 15,003 15,055

Selling, general and

administrative 1,861 1,373 6,727 4,675

Total operating costs

and expenses 7,466 6,443 28,060 23,851

Loss from operations (4,292) (3,809) (16,706) (16,519)

Interest income, net 101 640 1,195 1,700

Net loss (4,191) (3,169) (15,511) (14,819)

Deemed dividend to

Series C

preferred shareholders -- -- -- (19,114)

Net loss allocable

to common shareholders $(4,191) $(3,169) $(15,511) $(33,933)

Basic and diluted

net loss per

common share $(0.16) $(0.12) $(0.60) $(2.14)

Shares used in

computing basic and

diluted net loss

per common share 26,173 25,352 25,939 15,859



Pro forma basic and

diluted net loss

per common share (A) $(0.16) $(0.12) $(0.60) $(1.56)

Shares used in

computing basic and

diluted pro forma net

loss per

common share (A) 26,173 25,352 25,939 21,756





(A) Assumes conversion of preferred stock into common stock at date of

issuance. The preferred stock automatically converted to common

stock upon the initial public offering of the Company`s common

stock.





CEPHEID



CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)



ASSETS



December 31, December 31,

2001 2000 (B)

(unaudited)

Current assets:

Cash and cash equivalents $15,905 $39,698

Short term investments 8,775 --

Restricted cash 661 --

Accounts receivable 2,020 2,407

Inventory 3,568 1,772

Prepaid expenses and other current assets 338 530

Total current assets 31,267 44,407

Property and equipment, net 3,175 2,892

Other assets 50 54

Total assets $34,492 $47,353



LIABILITIES AND SHAREHOLDERS` EQUITY

Current liabilities:

Accounts payable $587 $501

Accrued compensation 778 510

Accrued other liabilities 1,399 1,236

Current portion of equipment financing 1,029 879

Current portion of deferred rent 32 22

Total current liabilities 3,825 3,148

Equipment financing, less current portion 1,167 1,504

Deferred rent, less current portion 22 54



Shareholders` equity:

Common stock 65,459 64,944

Additional paid-in capital 7,694 8,310

Notes receivable from shareholder -- (35)

Deferred stock-based compensation (833) (3,238)

Accumulated other comprehensive loss (7) (10)

Accumulated deficit (42,835) (27,324)

Total shareholders` equity 29,478 42,647

Total liabilities and shareholders` equity $34,492 $47,353





(B) The balance sheet at December 31, 2000 has been derived from the

audited financial statements which are included in the Company`s

Form 10-K filed with the Securities and Exchange Commission.



MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X38851598

SOURCE Cepheid



CONTACT: Cathy Smith, CFO of Cepheid, [phone], ext. 230



URL: http://www.cepheid.com

http://www.prnewswire.com


Copyright (C) 2002 PR Newswire. All rights reserved.

ciao luna

[ABCSchuetze]

schau mal hier nach http://www.boersen-community.de.vu/

[luna3636]

nach dem gestrigen heftigen kursrutsch geht`s heute wieder nach norden

akt. in usa bei + 26 % :

"CPHD",3.05,"2/7/2002","11:45am",+0.63,2.75,3.06,2.61,621700


auslöser ist offensichtlich neben der techn. reaktion folgende meldung, die ich eben bei yahoo gefunden habe:

8:59AM Cepheid upped by UBS; cites market visibility, govt spending (CPHD) 2.42: UBS Warburg upgrades to BUY from Hold with a $5 target; cites compelling valuationand improving visibility into market factors that could effect purchases of rapid, on-site DNA collection technologies; also notes increased federal budget for bio-threat projects.

ciao luna